OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SCNX$0.4159

Scienture Holdings Inc

PharmaceuticalsVerified

Scienture Holdings Inc has a market capitalization of $16.7 million and a price-to-earnings ratio of 0.79, indicating a relatively low valuation compared to earnings. The company's price-to-book ratio is 1.23, suggesting that the market value is slightly above the book value of its equity. The company's liquidity position is characterized by a current ratio of 4.75, which is significantly above the industry median, indicating strong short-term liquidity. However, the company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. In terms of profitability, the company reported a net income of $21.25 million, but this was offset by an operating loss of $5.49 million, indicating that operational efficiency is a concern. The return on equity (ROE) is 1.56, and the return on assets (ROA) is 1.27, both of which are below the industry median, suggesting that the company is not generating strong returns relative to its equity and asset base. The company's operating cash flow is negative at -$10.19 million, and its free cash flow is -$21.80 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream at this time. The company's capital expenditure of -$2.50 million indicates that it is investing in its operations, but the lack of revenue raises questions about the sustainability of these investments. The company's geographic exposure is not disclosed, but the absence of revenue data suggests that the company may be in an early stage of development or may be facing significant market challenges. Looking ahead, the company's growth trajectory is uncertain. The lack of revenue and the negative operating cash flow suggest that the company may need to secure additional financing to continue operations. The company's liquidity position is currently strong, with a current ratio of 4.75, but the negative free cash flow indicates that this may not be sustainable in the long term. The company's risk assessment indicates low liquidity and dilution risk, but the absence of revenue and the negative operating cash flow suggest that the company may face significant financial challenges in the future. Recent events and filings do not indicate any immediate liquidity or dilution risks, but the company's financial performance raises concerns about its long-term viability. The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future. The company's profitability metrics are weak, and the lack of revenue suggests that the company may need to pivot its business model or secure new revenue streams to remain competitive.

30-day price · SCNX(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyScienture Holdings Inc
TickerSCNX.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Scienture Holdings Inc is a company in the Pharmaceuticals & Medical Research industry, primarily engaged in the development and commercialization of medical technologies and pharmaceutical products.

Classification. Scienture is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Scienture Holdings Inc has a market capitalization of $16.7 million and a price-to-earnings ratio of 0.79, indicating a relatively low valuation compared to earnings. The company's price-to-book ratio is 1.23, suggesting that the market value is slightly above the book value of its equity. The company's liquidity position is characterized by a current ratio of 4.75, which is significantly above the industry median, indicating strong short-term liquidity. However, the company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. In terms of profitability, the company reported a net income of $21.25 million, but this was offset by an operating loss of $5.49 million, indicating that operational efficiency is a concern. The return on equity (ROE) is 1.56, and the return on assets (ROA) is 1.27, both of which are below the industry median, suggesting that the company is not generating strong returns relative to its equity and asset base. The company's operating cash flow is negative at -$10.19 million, and its free cash flow is -$21.80 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream at this time. The company's capital expenditure of -$2.50 million indicates that it is investing in its operations, but the lack of revenue raises questions about the sustainability of these investments. The company's geographic exposure is not disclosed, but the absence of revenue data suggests that the company may be in an early stage of development or may be facing significant market challenges. Looking ahead, the company's growth trajectory is uncertain. The lack of revenue and the negative operating cash flow suggest that the company may need to secure additional financing to continue operations. The company's liquidity position is currently strong, with a current ratio of 4.75, but the negative free cash flow indicates that this may not be sustainable in the long term. The company's risk assessment indicates low liquidity and dilution risk, but the absence of revenue and the negative operating cash flow suggest that the company may face significant financial challenges in the future. Recent events and filings do not indicate any immediate liquidity or dilution risks, but the company's financial performance raises concerns about its long-term viability. The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future. The company's profitability metrics are weak, and the lack of revenue suggests that the company may need to pivot its business model or secure new revenue streams to remain competitive.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 4.75, but this is offset by negative operating and free cash flows.
  • The company's profitability metrics, including ROE and ROA, are below the industry median, indicating weak returns.
  • The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream.
  • The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future.
  • The company's growth trajectory is uncertain, and the lack of revenue and negative cash flows suggest that the company may face significant financial challenges.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit$0.00
Operating income-$5.5M
Net income$21.2M
R&D
SG&A
D&A
SBC
Operating cash flow-$10.2M
CapEx-$2.5M
Free cash flow-$21.8M
Total assets$16.7M
Total liabilities$3.1M
Total equity$13.6M
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.9M-$5.3M-$5.3M-$5.3M
FY-3$10.3M-$2.9M-$3.5M-$2.4M
FY-2$1.4M-$4.4M-$17.8M-$7.6M
FY-1$136.6k-$17.2M$9.1M-$35.6M
FY0$431.6k-$42.9M-$41.5M-$41.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$5.8M$3.8M
FY-3$3.7M$763.1k
FY-2$12.5M$542.4k
FY-1$104.9M$79.1M
FY0$84.2M$70.1M
PeriodOCFCapExFCFSBC
FY-4-$2.6M-$22.6k-$5.3M
FY-3-$1.6M-$2.4M
FY-2-$2.2M-$7.6M
FY-1-$14.3M-$2.5M-$35.6M
FY0-$13.4M$0.00-$41.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$5.5M$21.2M-$21.8M
FQ-6$18.7k-$1.5M-$1.8M-$1.6M
FQ-5$64.9k-$3.5M-$3.2M-$5.4M
FQ-4$53.1k-$6.7M-$7.2M-$6.8M
FQ-3$10.3k-$3.7M-$3.1M-$3.1M
FQ-2$0.00-$5.5M-$6.7M-$6.7M
FQ-1$590.0k-$4.2M-$3.6M-$3.6M
FQ0-$29.5M-$28.1M-$27.7M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$16.7M$13.6M
FQ-6$14.8M$11.8M
FQ-5$94.3M$85.1M
FQ-4$104.9M$79.1M
FQ-3$106.4M$81.2M
FQ-2$104.3M$77.9M
FQ-1$104.8M$82.7M
FQ0$84.2M$70.1M
PeriodOCFCapExFCFSBC
FQ-7-$10.2M-$2.5M-$21.8M
FQ-6-$6.0M-$2.5M-$1.6M
FQ-5-$11.4M-$2.5M-$5.4M
FQ-4-$14.3M-$2.5M-$6.8M
FQ-3-$3.0M-$3.1M
FQ-2-$5.0M$0.00-$6.7M
FQ-1-$8.2M-$3.6M
FQ0-$13.4M$0.00-$27.7M
Valuation
Market price$0.41
Market cap$16.7M
Enterprise value
P/E0.8
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B1.2
P/Tangible book1.2
Tangible book$13.6M
Net cash
Current ratio4.8
Debt/Equity0.0
ROA1.3%
ROE1.6%
Cash conversion-48.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSCNXActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Observations
IR observations
Mean price target1.50 USD
Median price target1.50 USD
High price target1.50 USD
Low price target1.50 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.72 USD
Last actual EPS-0.97 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 23:24 UTC#a675920f
Market quoteclose USD 0.39
no public URL
2026-05-16 23:24 UTC#fc600fda
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 08:34 UTCJob: 8644d7da